Sana Biotechnology, Inc. $SANA Position Boosted by Baillie Gifford & Co.

Baillie Gifford & Co. boosted its holdings in Sana Biotechnology, Inc. (NASDAQ:SANA) by 13.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,436,503 shares of the company’s stock after acquiring an additional 1,371,775 shares during the quarter. Baillie Gifford & Co. owned 4.81% of Sana Biotechnology worth $40,600,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in SANA. Wealth Enhancement Advisory Services LLC grew its stake in shares of Sana Biotechnology by 4.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 52,872 shares of the company’s stock worth $188,000 after purchasing an additional 2,023 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Sana Biotechnology during the third quarter valued at about $39,000. SG Americas Securities LLC lifted its holdings in Sana Biotechnology by 21.3% in the third quarter. SG Americas Securities LLC now owns 100,258 shares of the company’s stock worth $356,000 after purchasing an additional 17,581 shares during the period. KLP Kapitalforvaltning AS bought a new position in Sana Biotechnology in the 3rd quarter valued at about $100,000. Finally, Griffin Asset Management Inc. bought a new position in Sana Biotechnology in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA opened at $4.83 on Friday. Sana Biotechnology, Inc. has a one year low of $1.26 and a one year high of $6.55. The stock has a fifty day moving average of $4.39 and a 200-day moving average of $4.13. The company has a market capitalization of $1.29 billion, a PE ratio of -4.98 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.03. As a group, research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen raised shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. Citizens Jmp raised their price objective on shares of Sana Biotechnology from $5.00 to $8.00 and gave the company a “market outperform” rating in a research note on Thursday, October 30th. Citigroup reissued an “outperform” rating on shares of Sana Biotechnology in a report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Finally, Bank of America lifted their price target on Sana Biotechnology from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.